

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

03 July 1998 (03.07.98)

International application No.

PCT/US97/20226

Applicant's or agent's file reference

97,707

International filing date (day/month/year)

12 November 1997 (12.11.97)

Priority date (day/month/year)

12 November 1996 (12.11.96)

Applicant

MADISON, Edwin, L.

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

10 June 1998 (10.06.98)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Maria Victoria CORTIELLO

Telephone No.: (41-22) 338.83.38

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/72	A2	(11) International Publication Number: WO 98/21320 (43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/US97/20226 (22) International Filing Date: 12 November 1997 (12.11.97) (30) Priority Data: 60/030,655 12 November 1996 (12.11.96) US (71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US). (74) Agent: ZIMMERMAN, Roger; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE (57) Abstract <p>Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/72 // 15/55		A3	(11) International Publication Number: WO 98/21320
			(43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/US97/20226		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 November 1997 (12.11.97)			
(30) Priority Data: 60/030,655 12 November 1996 (12.11.96) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/030,655 (CIP) Filed on 12 November 1996 (12.11.96)			
(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventor; and (75) Inventor/Applicant (for US only): MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US).		(88) Date of publication of the international search report: 9 July 1998 (09.07.98)	
(74) Agent: ZIMMERMAN, Roger, McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).			
(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE			
(57) Abstract Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China			PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/72 // 15/55	A3	(11) International Publication Number: WO 98/21320 (43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/US97/20226 (22) International Filing Date: 12 November 1997 (12.11.97) (30) Priority Data: 60/030,655 12 November 1996 (12.11.96) US (71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US). (74) Agent: ZIMMERMAN, Roger; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 9 July 1998 (09.07.98)	
(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE (57) Abstract <p>Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-I, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.</p>		

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 97/20226

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0199574 A		JP 7040940 B	10-05-95
		JP 62000024 A	06-01-87
		NO 175216 B	06-06-94
		PT 82429 B	03-03-88
		US 5736134 A	07-04-98
		US 5714372 A	03-02-98
		US 5073494 A	17-12-91
		US 5147643 A	15-09-92
		US 5219569 A	15-06-93
<hr/>			



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/72 // 15/55	A3	(11) International Publication Number: WO 98/21320 (43) International Publication Date: 22 May 1998 (22.05.98)
<p>(21) International Application Number: PCT/US97/20226</p> <p>(22) International Filing Date: 12 November 1997 (12.11.97)</p> <p>(30) Priority Data: 60/030,655 12 November 1996 (12.11.96) US</p> <p>(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US).</p> <p>(74) Agent: ZIMMERMAN, Roger; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 9 July 1998 (09.07.98)</p>	
<p>(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE</p> <p>(57) Abstract</p> <p>Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE

5

Reference to Related Application

This application claims the benefit of U.S. Provisional Application S.N. 60/030,655, filed November 12, 1996, which is incorporated by reference.

10 Governmental Rights

This invention was made with governmental support from the United States Government, National Institutes of Health, Grants HL52475 and HL31950; the United States Government has certain rights in the invention.

15 The invention comprises protein single chain variants of tissue type plasminogen activator, also referred to as t-PA as well as nucleic acids encoding such protein single chain variants of tissue type plasminogen activator. The t-PA protein variants have higher zymogenicity than the wild-type single chain t-PA form. Methods of making and using the t-PA variant compositions are also described.

20 Background

Tissue-type plasminogen activator (t-PA) is a serine protease that plays a critical role in the process of fibrinolysis, the dissolution of clots, by activating plasminogen to the protease plasmin. t-PA has been fully identified and characterized by underlying DNA sequence and deduced amino acid sequence. See Pennica et al., *Nature*, 301: 214 (1983) and U.S. Pat. No. 25 4,853,330, issued Aug. 1, 1989, the teachings of both of which are incorporated by reference. The nucleotide sequence and deduced primary amino acid sequence of human t-PA is depicted in Fig. 1A, Fig. 1B and Fig. 1C.

30 The group of amino acid residues from -35 to -1 preceding the sequence of the mature t-PA is the "pro" sequence. The mature t-PA molecule (amino acid residues 1-527) contains five domains that have been defined with reference to homologous or otherwise similar structures identified in various other proteins such as trypsin, chymotrypsin, plasminogen, prothrombin, fibronectin, and epidermal growth factor (EGF). These domains have been

designated, starting at the N-terminus of the amino acid sequence of mature t-PA, as 1) the finger region (F) that has variously been defined as including amino acid residues 1 to about 44, 2) the growth factor region (G) that has been variously defined as stretching from about amino acid residues 45 to 91 (based upon its homology with EGF), 3) kringle one (K1) that has been defined as stretching from about amino acid residue 92 to about amino acid residue 173, 4) kringle two (K2) that has been defined as stretching from about amino acid residue 180 to about amino acid residue 261, and 5) the so-called serine protease domain (P) that generally has been defined as stretching from about amino acid residue 264 to the C-terminal end of the molecule at amino acid residue 527. These domains, which are situated generally adjacent to one another, or are separated by short "linker" regions, account for the entire amino acid sequence of from 1 to 527 amino acid residues of the mature form of t-PA.

Each domain has been described variously as contributing certain specific biologically significant properties. The finger domain has been characterized as containing a sequence of at least major importance for high binding affinity to fibrin. (This activity is thought important for the high specificity that t-PA displays with respect to clot lysis at the locus of a fibrin-rich thrombus.) The growth factor-like region likewise has been associated with cell surface binding activity. The kringle 2 region also has been strongly associated with fibrin binding and with the ability of fibrin to stimulate the activity of t-PA. The serine protease domain is responsible for the enzymatic cleavage of plasminogen to produce plasmin.

t-PA is unusual among proteases in the level of the enzymatic activity of its precursor. In general, proteases are synthesized as zymogens, inactive precursors that must either be proteolytically processed or bind to a specific co-factor to develop substantial catalytic activity. The increase in catalytic efficiency after zymogen activation, or zymogenicity, is dramatic in almost all cases, although varying widely among individual members of the chymotrypsin family. For example, strong zymogens, i.e., those having high zymogenicity, such as trypsinogen, chymotrypsinogen, or plasminogen are almost completely inactive, with measured zymogenicities of 10^4 to 10^6 (Robinson, N. C., Neurath, H., and Walsh, K. A. (1973) *Biochemistry* 12, 420-426; Gertler, A., Walsh, K. A., and Neurath, H. (1974) *Biochemistry* 13, 1302-1310). Other serine proteases exhibit intermediate zymogenicity. For example, the enzymatic activity of Factor XIIa is 4000-fold greater than that of its corresponding zymogen, Factor XII (Silverberg, M., and Kaplan, A. P. (1982) *Blood* 60, 64), and the catalytic efficiency of urokinase is 250-fold greater than that of pro-urokinase (Lijnen, H. R., Van Hoef,

B., Nelles, L., and Collen, D. (1990) *J. Biol. Chem.* **265**, 5232-5236). By contrast, the catalytic activities of single and two chain t-PA vary by a factor of only 5-10.

The zymogenicity, expressed as the ratio of the activity of the mature cleaved two-chain enzyme to that of the single chain precursor form, is only 5-10 for wild-type t-PA, in contrast
5 to other precursors of other proteases that have little or no catalytic activity. Thus, the single chain form of wild-type t-PA is not a true zymogen.

There have been many attempts to improve the usefulness of t-PA by genetic engineering. These efforts have been only partially successful. The state of the art has been reviewed by Krause, J., & Tanswell, P. *Arzneim.-Forsch.* **39**: 632-637 (1989) and in U.S.
10 patent No. 5,616,486, the teachings of both of which are incorporated by reference.

Despite the profound advantages associated with natural t-PA as a clot-dissolving agent, it is not believed that the natural protein necessarily represents the optimal t-PA agent under all circumstances. Therefore, several variants have been proposed or devised to enhance specific properties of t-PA. Certain of those variants address disadvantages associated with the
15 use of natural t-PA in situations where an agent with a longer half-life or slower clearance rate would be preferred, e.g., in the treatment of deep-vein thrombosis and following reperfusion of an infarct victim, or where a single-chain agent is preferred.

For example, removal of a substantial portion or all of the finger domain results in a molecule with substantially diminished fibrin binding characteristics, albeit in return there is a
20 decrease in the overall rate of clearance of the resultant entity—See WO 89/00197 published Jan. 12, 1989.

Variants are described in EPO Pat. Publ. No. 199,574 that have amino acid substitutions at the proteolytic cleavage sites at positions 275, 276, and 277. These variants, characterized preferentially as t-PA variants having an amino acid other than arginine at
25 position 275, are referred to as protease-resistant one-chain t-PA variants in that, unlike natural t-PA, which can exist in either a one-chain or two-chain form, they are resistant to protease cleavage at position 275 and are therefore not converted metabolically in vivo into a two-chain form. This form is thought to have certain advantages biologically and commercially, in that it is more stable while the fibrin binding and fibrin stimulation are increased relative to
30 two-chain t-PA. Furthermore, plasminogen activators are described that comprise one domain capable of interacting with fibrin and the protease domain of urokinase, with one embodiment

being urokinase altered to make it less susceptible to forming two-chain urokinase. See WO 88/05081 published Jul. 14, 1988.

For further patent literature regarding modification of the protease cleavage site of t-PA, see, for example, EPO Pat.Nos. 241,209; EP 201,153 published Nov. 12, 1986; EP 233,013 published Aug. 19, 1987; EP 292,009 published Nov. 23, 1988; EP 293,936 published Dec. 7, 1988; and EP 293,934 published Dec. 7, 1988; and WO 88/10119.

Glycosylation mutants at positions 117-119, 184-186, and 448-450 exhibited higher specific activity as the mole percent carbohydrate was reduced. See EPO Pub. No. 227,462 published Jul. 1, 1987. This patent application additionally discloses using an assay of fibrin/fibrin degradation products and teaches that one may also modify the t-PA molecule at positions 272-280 or delete up to 25 amino acids from the C-terminus. Further, the t-PA mutants with Asn 119, Ala 186 and Asn 450, which have the N-glycosylation sites selectively removed by DNA modification but contain residual O-linked carbohydrate, were found to be about two-fold as potent as melanoma t-PA in an in vitro lysis assay. See EPO Publ. No. 225,286 published Jun. 10, 1987.

Replacement of the amino acid at position 449 of t-PA with any amino acid except arginine to modify the glycosylation site, as well as modification of Arg 275 or deletion of the - 3 to 91 region, is also taught. See WO 87/04722 published Aug. 13, 1987. An amino acid substitution at position 448 of t-PA is disclosed as desirable to remove glycosylation. See EPO Pub. No. 297,066 published Dec. 28, 1988. The combination of modifications at positions 448-450 and deletion of the N-terminal 1-82 amino acids is disclosed by WO 89/00191 published Jan. 12, 1989. Additionally, urokinase has been modified in the region of Asp 302 -Ser 303 -Thr 304 to prevent glycosylation. See EPO Pub. No. 299,706 published Jan. 18, 1989.

However, alteration of the glycosylation sites, and in particular that at amino acid 117, seems invariably to result in a molecule having affected solubility characteristics that may result additionally in an altered circulating half-life pattern and/or fibrin binding characteristics. See EPO Pat. Publ. No. 238,304, published Sep. 23, 1987.

When the growth factor domain of t-PA is deleted, the resultant variant is still active and binds to fibrin, as reported by A. J. van Zonneveld et al., *Thrombos. Haemostas.* 54 (1): 4 (1985). Various deletions in the growth factor domain have also been reported in the patent literature. See EPO Publ. No. 241,209 (del-51-87), EPO Publ. No. 241,208 (del-51-87 and

del-51-173), PCT 87/04722 (deletion of all or part of the N-terminal 1 - 91), EPO Publ. No. 231,624 (all of growth factor domain deleted), and EPO Publ. No. 242,836 and Jap. Pat. Appl. Kokai No. 62 - 269688 (some or all of the growth factor domain deleted).

5 It has further been shown that t-PA can be modified both in the region of the first kringle domain and in the growth factor domain, resulting in increased circulatory half-life. See EPO Pat. Publ. No. 241,208 published Oct. 14, 1987. The region between amino acids 51 and 87, inclusive, can be deleted from t-PA to result in a variant having slower clearance from plasma. Browne et al., *J. Biol. Chem.*, **263**: 1599-1602 (1988). Also, t-PA can be modified, without adverse biological effects, in the region of amino acids 67 to 69 of the
10 mature, native t-PA, by deletion of certain amino acid residues or replacement of one or more amino acids with different amino acids. See EPO Pat. Publ. No. 240,334 published Oct. 7, 1987.

A hybrid of t-PA/urokinase using the region of t-PA encompassing amino acids 273 - 527 is also disclosed. See EPO 290,118 published Nov. 9, 1988. Serpin-resistant mutants of
15 human t-PA with alterations in the protease domain, including del296-302 t-PA, R304S t-PA, and R304E t-PA, are disclosed in Madison et al., *Nature*, **339**: 721-724 (1989). The above list is not an exhaustive review of the numerous variants of t-PA that have described.

As a result of the catalytic activity of precursor t-PA, despite effective clot lysis at targeted sites, nondesirable proteolysis occurs systemically resulting in the deleterious
20 depletion of circulating fibrinogen, α 2-anti-plasmin and plasminogen. What is needed are more zymogenic t-PA variant proteins that provide effective local clot lysis is achieved with diminished systemic proteolytic effects.

Summary of the Invention

25

The present invention provides single chain variant t-PA proteins having at least two substitutions of basic amino acid residues by neutral or acidic amino acid residues, compared to the wild-type human t-PA, as well as polynucleotides encoding such single chain variant t-PA proteins. The single chain variant t-PA proteins of the present invention have the R275
30 amino acid residue substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. Preferably the single chain variant t-PA proteins of the present invention have the R275 amino

acid residue substituted by an amino acid residue chosen from the group consisting of an aspartic acid residue and a glutamic acid residue, and most preferably by a glutamic acid residue.

5 The single chain variant t-PA proteins of the present invention have additionally at least one other basic amino acid residue in the serine protease region residue substituted by a non-basic amino acid such that the salt bridge interaction normally found in wildtype single chain t-PA between aspartate 477 and lysine 429 is disrupted. Preferably, basic amino acids are replaced with polar or acidic amino acids, and more preferably, amino acid residues chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine,
10 aspartic acid and glutamic acid.

The salt bridge interaction between aspartate 477 and lysine 429 can be disrupted by a substitution at position 477 or 429, or by an appropriate substitution at a position within the serine protease region that provides an alternative salt bridge interaction partner for at least one of aspartate 477 and lysine 429. In one preferred embodiment, the H417 amino acid residue is
15 substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. More preferably the single chain variant t-PA proteins of the present invention have both the R275 amino acid residue and the H417 amino acid residue substituted by an amino acid residue chosen from the group consisting of an aspartic acid residue and a glutamic acid residue. Two exemplary
20 preferred single chain variant t-PA proteins are the t-PA variants designated as R275E,H417E and R275E,H417D.

In another preferred embodiment, the K429 amino acid residue is substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. More preferably the single chain variant
25 t-PA proteins of the present invention have both the R275 amino acid residue and the K429 amino acid residue substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. One preferred single chain variant t-PA protein is the t-PA variant designated as R275E,K429Y.

30 The single chain variant t-PA proteins of the present invention exhibit greater zymogenicity, expressed as the ratio of the activity of the mature cleaved two-chain enzyme to that of the single chain precursor form, than that of the wild type single chain t-PA protein.

The single chain variant t-PA proteins of the present invention have zymogenicity of at least 10, preferably about 50 to about 200.

5 The single chain variant t-PA proteins of the present invention exhibit a greater fibrin stimulation factor, expressed as the ratio of the catalytic efficiencies in the presence and absence of fibrin, compared to the wild type single chain t-PA protein. The single chain variant t-PA proteins of the present invention have a fibrin stimulation factor of at least 7,000, preferably about 20,000 to about 50,000.

10 The single chain variant t-PA proteins of the present invention exhibit a reduced inhibition by plasminogen activator inhibitor 1 (PAI-1) to the wild type single chain t-PA protein. The single chain variant t-PA proteins of the present invention are at least a factor of 5, preferably at least a factor of about 9, most preferably at least a factor of about 200 less inhibited by PAI-1 compared to the wild type single chain t-PA protein.

15 The single chain variant t-PA proteins of the present invention exhibit a greater fibrin selectivity factor, expressed as the ratio of the catalytic efficiencies in the presence fibrin to that in the presence of fibrinogen, compared to the wild type single chain t-PA protein. Preferred embodiments of the single chain variant t-PA proteins of the present invention have a fibrin selectivity factor of at least 10, preferably at least 50, more preferably at least 100.

Brief Description of the Drawings

20 In the drawings,

Figs. 1A, 1B and 1C show the nucleotide sequence and deduced amino acid sequence of the full-length human t-PA cDNA; and

25 Fig. 2 is a graphical representation of the results of standard chromogenic assays of plasminogen activation in the presence of buffer (open squares), DESAFIB (open diamonds), fibrinogen (open circles), cyanogen bromide fragments of fibrinogen (open triangles) or the stimulatory peptide P368 (hatched squares).

Detailed Description of the Preferred Embodiments

30 As used herein, "wild-type t-PA" refers to the t-PA protein naturally occurring in humans. While this human t-PA is exemplified by the amino acid sequence depicted in Figs. 1A, 1B and 1C, the term wild-type t-PA should be understood to encompass naturally occurring allelic variations.

t-PA Variant Compositions

The t-PA variant cDNAs and the corresponding expressed recombinant proteins of this invention are useful compounds that function in the serine protease-mediated control of fibrinolysis as described herein.

5 The t-PA variant cDNAs of the present invention contain at least one nucleotide substitution to generate a t-PA cDNA that encodes a noncleavable single chain t-PA variant, i.e., not cleavable by plasmin under normal conditions. The nucleotide substitution results in a substitution of a glutamic acid (E) for an arginine (R) at amino acid residue 275 (or position 15 using the chymotrypsin numbering system) in the t-PA precursor that is responsible for
10 creating a noncleavable variant. Positions 15, 144, 156, and 194 of the chymotrypsin numbering system correspond to positions 275, 417, 429, and 477, respectively, in the t-PA numbering system as depicted in Fig. 1.

15 The variants, which are substitution mutants, are designated by the single letter code of the wild type human t-PA amino acid residue, the position of the residue relative to the amino terminus of the mature human t-PA as depicted in Fig. 1, followed by the single letter code of the amino acid residue substituted for the amino acid residue in mature human t-PA. The substitution of glutamic acid for arginine at position 275 is designated as R275E. Equivalent substitutions generating noncleavable single chain t-PA are known in the art (Higgins, D.L., et al., (1990) *Thrombosis Res.* 57: 527-539).

20 In addition to the R275E substitution, the variant cDNAs of the present invention further comprise at least one other nucleotide substitution at a separate site to create a t-PA variant having at least two amino acid substitutions. Preferred cDNA variants include at least one nucleotide substitution that results in an amino acid substitution of an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid for a histidine at amino acid residue position 417. Preferred
25 embodiments are designated R275E,H417D and R275E,H417E. A further cDNA variant comprises at least one nucleotide substitution resulting in the substitution of an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid for the lysine (K) at amino acid residue position
30 429. One such preferred embodiment is designated R275E,K429Y.

The variant t-PA cDNAs of the present invention are useful for generating the recombinant expressed variant t-PAs described above. In a further embodiment, the variant t-PA cDNAs have therapeutic uses in gene therapy as described below.

5 The invention includes embodiments such as expression vectors or plasmids in which the cDNAs for encoding variant t-PAs are operably linked to provide for the expression of recombinant variant t-PAs for use in the methods as described below. One preferred embodiment is the expression of a variant t-PA protein by COS 1 cells comprising pSVT7 expression vector operably linked to a polynucleotide encoding the variant protein. Constitutive and inducible expression vectors are disclosed. In a further embodiment,
10 transiently and stably transfected cells contain cDNA encoding variant t-PAs.

The resultant recombinant expressed t-PA variants described herein are characterized as having one or more of the following structural and functional properties: 1) The t-PA variant is in the form of a noncleavable single chain protein containing an R275E amino acid substitution or equivalents thereof that prevent cleavage by t-PA activating enzymes; 2) The t-PA variant exhibits increased resistance to inhibition by the serpin plasminogen activator inhibitor, type I (PAI-1); 3) The t-PA variants has diminished catalytic activity on substrates, such as plasminogen, in the absence of co-factors, such as fibrin; 4) The t-PA variants exhibit enhanced stimulation by fibrin; 5) The t-PA variants exhibit comparable catalytic activity to substrates, such as plasminogen, in the presence of co-factors, such as fibrin; and 6) In view of
15 the proceeding properties, the t-PA variants thus are effective at local fibrinolysis function without extensive systemic proteolysis thereby negating the depletion of circulating fibrinogen, α 2-anti-plasmin and plasminogen, as is seen with wild type human single chain t-PA precursor.
20

Preferred recombinant expressed t-PA variants thus include R275E,H417D, R275E,H417E and R275E,K429Y, and conservative substitutions thereof. In general,
25 examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as
30 lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another. For further discussion of the classifications of

amino acids see Lehninger, A.L., Biochemistry, 2nd Edition, Worth Publishers, New York, 1975, pp.71-94.

The phrase "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue provided that such protein displays the requisite binding activity. "Chemical derivative" refers to a subject protein having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example, 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. D-amino acids may also be included in place of one or more L-amino acids.

In the specific case of the present invention, basic amino acids, i.e., arginine, lysine and histidine are replaced with non-basic amino acids. Preferably basic amino acids are replaced with polar or acidic amino acids, i.e. amino acid residues chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid and glutamic acid. Conservative substitutions are thus defined, for the purpose of the present invention, as meaning that non-basic amino acids replacing particular basic amino acids in mature wild type human t-PA may be chosen from the group of non-basic amino acids generally, preferably from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid and glutamic acid, and more preferably from the group consisting of tyrosine, aspartic acid and glutamic acid. For example, the use of aspartic acid instead of glutamic acid to replace an histidine residue is a conservative substitution. Preferred variants are R275E,H417D and R275E,H417E, described in Example 1 and the R275E,K429Y variant, described in Example 2.

The expressed recombinant t-PA variants having at least two amino acid substitutions, e.g., R275E,H417D, R275E,H417E and R275E,K429Y, further exhibit unique properties. R275E and R275E,H417E are activated by both fibrinogen and fibrin while R275E,K429Y is activated primarily by fibrin and is not sensitive to fibrinogen. The latter is also more resistant than the R275E,H417D and R275E,H417E variants to inhibition by PAI-1. These characteristics provide additional advantages in administering the compounds as therapeutic thrombolytic compositions as further described below. In addition, the t-PA variants described herein are useful in diagnostic applications as described below.

10 Methods of making and Using t-PA Variant Compositions

Methods of Making

The t-PA variant cDNA and recombinant expressed variant proteins described above are useful in a number of methodological aspects as described in Examples 1 and 2. In particular, the isolated cDNA clones are useful in an expression vector system to produce encoded t-PA variant proteins of this invention. Thus, expression vector systems having a t-PA variant cDNA operably linked therein, including cells containing the expression vectors, are contemplated for generating the recombinant expressed variant proteins of this invention.

Diagnostic Applications

20

Preferred diagnostic methodological aspects are described herein. In particular, the recombinant expressed t-PA variants of the present invention are useful in diagnostic assays to detect fibrin and fibrin degradation products that have altered activities. The assays are thus indicated in thrombotic conditions. Other diagnostic applications, including kits comprising antibodies against the t-PA variants are familiar to one of ordinary skill in the art.

25

Therapeutic Applications

The t-PA variant cDNAs of the present invention are useful in genetic therapeutic applications for use in ameliorating thrombotic disorders including both acute and chronic conditions. Acute conditions include among others both heart attack and stroke while chronic situations include those of arterial and deep vein thrombosis and restenosis. Preferred

30

therapeutic compositions thus include the cDNA compounds themselves as naked DNA, presented as part of a viral vector delivery system or other vector-based gene expression delivery system, presented in a liposome delivery system and the like.

5 The recombinant expressed t-PA variant proteins of the present invention are contemplated as thrombolytic therapeutic agents for ameliorating the same conditions outlined above. Based on the individual structural and functional properties of various t-PA variant proteins described above, the selection of the particular t-PA variant is determined by the desired therapeutic outcome. For example, the fibrinogen-mediated activation of endogenous human t-PA is activated by bleeding which then results in a widespread undesired systemic response. Thus, to mediate fibrinolytic processes locally in either an acute or chronic thrombotic condition while simultaneously preventing proteolytic activation systemically, one would therefore use the t-PA variant, namely R275E,K429Y, that is primarily activated by fibrin and not fibrinogen. A composition for use as thrombolytic therapeutic agents generally a physiologically effective amount of the t-PA variant protein in a pharmaceutically suitable excipient. Depending on the mode of administration and the condition to be treated, the thrombolytic therapeutic agents are administered in single or multiple doses. If "bolus" doses are administered, doses of about 0.01 to about 0.6 mg/kg will typically be administered, preferably doses of about 0.05 to about 0.2 mg/kg, with subsequent administrations of about 0.1 to about 0.2 mg/kg to maintain a t-PA blood level of about 3 microgram/ml. One skilled in the art will appreciate that variations in dosage depend on the condition to be treated. In other applications, a composition of variant t-PA in a gel composition is useful in preventing the formation of adhesions.

Other variations and uses of the present invention will be apparent to one skilled in the art.

25

Example 1

Site Directed Mutagenesis And Construction Of Expression Vectors Encoding Variants Of T-PA

Oligonucleotide directed site specific mutagenesis was performed by the method of Zoller and Smith (Zoller, M. I., and Smith, M. (1984) DNA 3, 479-488) as modified by Kunkel (Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 488-492). Mutations were introduced into the 290 bp *SacI* - *SmaI* fragment of cDNA encoding t-PA that had been

30

previously subcloned into bacteriophage M13mp18. The mutagenic primers had the following nucleotide sequences:

H417D: 5' - CTACGGCAAGGACGAGGCCTTGT - 3' (SEQ ID NO: 8)

H417E: 5' - CTACGGCAAGGAGGAGGCCTTGT - 3' (SEQ ID NO: 9)

5 Following mutagenesis, ssDNA corresponding to the entire 290 bp *SacI* - *SmaI* fragment was fully sequenced to assure the presence of the desired mutation and the absence of any additional mutations. The sequence corresponding to the 290 bp *SacI* - *SmaI* fragment of the H417D mutation is shown in SEQ ID NO: 5; the corresponding sequence of the H417E mutation is shown in SEQ ID NO: 6. Replicative form (RF) DNA was prepared for
10 appropriate phage, and the mutated 290 bp *SacI* - *SmaI* fragments were recovered after digestion of RF DNA with *SacI* and *SmaI* and electrophoresis of the digestion products on an agarose gel. The isolated, mutated *SacI* - *SmaI* fragments were used to replace the corresponding fragment in full length cDNAs encoding wild type human t-PA or t-PA/R275E to yield new, full length cDNAs encoding t-PA/H417D; t-PA/H417E; t-PA/R275E,H417D
15 (SEQ ID NO: 1); and t-PA/R275E,H417E (SEQ ID NO: 2).

Expression of enzymes by transient transfection of COS cells.

cDNAs encoding t-PA; t-PA/R275E; t-PA/H417D; t-PA/H417E; t-PA/R275E,H417D; and t-PA/R275E were ligated into the transient expression vector pSVT7 which is described in
20 Madison, E. L., et al. (1989) *Nature* 339, 721-724; Bird, P.M., et al., (1987) *J. Cell Biol.* 105: 2905-2914; and Sambrook, J., et al., (1986) *Mol. Biol. Med.* 3: 459-481. See also U.S. Pat. No. 5,550,042, incorporated herein by reference, which describes the construction and use of pSVT7 as well as the deposit with American Type Culture Collection, 12301 Parklawn Dr., Rockville, MD 20852 of cultures comprising other pSVT7 t-PA constructs. Vectors with
25 ligated cDNA inserts were then introduced into COS 1 cells by electroporation using a Bio Rad Gene Pulser. An aliquot containing 20 µg of cDNA, 100 µg of carrier DNA and approximately 10⁷ COS cells were placed into a 0.4 cm cuvette, and electroporation was performed at 320 V, 960 µFD, and $\Omega = \infty$. Following electroporation, cells were incubated overnight at 37 degrees Celsius in DMEM containing 10% fetal calf serum and 5 mM sodium
30 butyrate. Cells were then washed with serum free medium and incubated in DMEM for 48 hours at 37 degrees Celsius. After the incubation with serum free media, conditioned media

were collected. Enzyme concentrations in aliquots of the the collected conditioned media were determined by ELISA.

Kinetic analysis of plasminogen activation using indirect chromogenic assays.

5 Indirect chromogenic assays of t-PA utilized the substrates lys-plasminogen (American Diagnostica, Greenwich, CT) and Spectrozyme PL (American Diagnostica) and were performed as previously described (Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M.-J., and Sambrook, J. F. (1989) *Nature* **339**, 721-724; Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M. J., Sambrook, J. F., and Bassel-Duby, R. S. (1990) *Proc. Natl. Acad. Sci. U.S.A.* **87**, 3530-3533; Madison, E. L., Goldsmith, E. J., Gething, M. J., Sambrook, J. F., and Gerard, R. D. (1990) *J. Biol. Chem.* **265**, 21423-21426.). Assays were performed both in the presence and absence of the co-factor DESAFIB (American Diagnostica). The concentration of lys-plasminogen was varied from 0.0125 – 0.2 μ M in the presence of DESAFIB and from 0.9 – 15 μ M in the absence of the co-factor.

15

Kinetic analysis of t-PA activity using a small, synthetic substrate

The direct chromogenic assay utilized the substrate methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroaniline (Spectrozyme t-PA, American Diagnostica) and was performed as previously described (Strandberg, L., and Madison, E. L. (1995) *J. Biol. Chem.* **270**, 23444-23449; Smith, J. W., Tachias, K., and Madison, E. L. (1995) *J. Biol. Chem.* **270**, 30486-30490).

20

Measurement of second order rate constants for inhibition by PAI-1

25 Second order rate constants for the inhibition of wild type human t-PA and variant t-PA were measured under pseudo-first order conditions as previously described. Briefly, enzyme and inhibitor were preincubated at 23 degrees Celsius for periods of time varying from 0 – 30 minutes. Following preincubation, the mixtures were diluted, and the residual enzymatic activity was measured in a standard indirect chromogenic assay. For each enzyme, the concentrations of enzyme and inhibitor and the times of preincubation were chosen to yield several data points for which the residual enzymatic activity varied between 20% and 80% of

30

the initial activity. Data were analyzed by plotting the natural logarithm of the ratio (residual activity/initial activity) versus time of preincubation and measuring the resulting slopes. Division of this slope by $-[I]$ yielded the second order rate constants shown.

5 It was found that replacement of histidine 417 of t-PA with an acidic residue selectively suppresses the catalytic activity of single chain t-PA. Histidine 417 was replaced by either an aspartate or glutamate residue to yield two variants: t-PA/H417D and t-PA/H417E. Accurate measurement of the enzymatic activity toward plasminogen of the single chain form of these two variants proved difficult, however, because the plasmin produced in this assay rapidly converted the single chain enzymes into their mature, two-chain form by
10 cleaving the R275-I276 peptide bond. Consequently, to overcome this technical difficulty, we also constructed noncleavable forms of the two mutated enzymes by introducing the additional mutation R275E into the existing mutants.

Wild type human t-PA, t-PA/R275E, and all four variants containing mutations at position 417 were expressed by transient expression of COS-1 cells. Since this procedure
15 yielded predominantly single chain enzymes, two-chain t-PAs were generated by treating the enzyme preparations with plasmin-Sepharose (Strandberg, L., and Madison, E. L. (1995) *J. Biol. Chem.* **270**, 23444-23449). Quantitative conversion of the enzymes into their mature, two-chain form was confirmed by SDS-PAGE. As expected, variants containing the mutation R275E were synthesized and secreted exclusively as single chain enzymes and were not
20 cleaved by plasmin-Sepharose.

The enzymatic activity of the single and two-chain forms of wild type human t-PA and each variant toward a small synthetic substrate is listed in Table I below. Mutation of histidine 417 had only very modest effects on the activity of the two-chain enzymes. Two-chain t-PA/H417D and t-PA/H417E displayed 67% or 80%, respectively, the activity of the two-
25 chain, wild type human t-PA enzyme in this assay. The H417D and H417E mutations, however, had more significant effects on the activities of the single chain enzymes. Compared to single chain t-PA/R275E, single chain t-PA/R275E,H417D (SEQ ID NO: 1) and t-PA/R275E,H417E (SEQ ID NO: 2) exhibited approximately 16% or 25%, respectively, the activity of single chain t-PA/R275E.

30

Table 1

*Kinetic constants for cleavage of the chromogenic substrate
Spectrozyme t-PA by single- and two-chain t-PA variants*

Enzyme	K_{cat} (s^{-1})	K_m (mM)	K_{cat}/K_m ($M^{-1}s^{-1}$)
Two-chain form			
t-PA	59	0.4	1.5×10^5
t-PA/H417D	41	0.4	1.0×10^5
t-PA/H417E	58	0.5	1.2×10^5
Single-chain form			
t-PA/R275E	26	0.7	3.7×10^4
t-PA/R275E,H417D	5.9	1.0	5.9×10^3
t-PA/R275E,H417E	12	1.3	9.2×10^3

All of the variants analyzed maintained high enzymatic activity towards the natural substrate, plasminogen, in the presence of the co-factor fibrin (Table II below). The catalytic activity of the two-chain form of wild type human t-PA, t-PA/H417D, and t-PA/H417E varied by a factor of only 1.4. Similarly, the activities of single chain t-PA/R275E, t-PA/R275E,H417D, and t-PA/R275E,H417E differed by a factor of less than 1.8.

Table II

*Kinetic constants for activation of plasminogen by single- and
two-chain t-PA variants in the presence of fibrin*

Enzyme	K_{cat} (s^{-1})	K_m (μM)	K_{cat}/K_m ($M^{-1}s^{-1}$)
Two-chain form			
t-PA	0.11	0.017	6.5×10^6
t-PA/H417D	0.11	0.024	4.6×10^6
t-PA/H417E	0.10	0.022	4.5×10^6
Single-chain form			
t-PA/R275E	0.16	0.017	9.4×10^6
t-PA/R275E,H417D	0.23	0.043	5.3×10^6
t-PA/R275E,H417E	0.17	0.028	6.1×10^6

In the absence of a co-factor, the mutations at position 417 had little effect on the activity of two-chain t-PA toward plasminogen; however, these mutations significantly reduced the catalytic efficiency of single chain t-PA (Table III below). Compared to that of single chain t-PA/R275E, the activity of t-PA/R275E,H417D and t-PA/R275E,H417E was reduced by a factor of approximately 14 or 6, respectively. In this assay, the "zymogenicity", or ratio of the activities of the two-chain and single chain form of a particular enzyme, were approximately 9 for wild type t-PA. By contrast, for variants containing the H417D or H417E mutation, this ratio increased to approximately 150 or 50, respectively (Table III).

Table III
Kinetic constants for activation of plasminogen by single- and two-chain variants of t-PA in the absence of a cofactor

Enzyme	$K_{cat}(s^{-1})$	$K_m(\mu M)$	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	0.093	6.7	1.4×10^4
t-PA/H417D	0.110	6.8	1.6×10^4
t-PA/H417E	0.099	8.7	1.1×10^4
Single-chain form			
t-PA/R275E	0.014	9.5	1.5×10^3
t-PA/R275E,H417D	0.001	9.4	1.1×10^2
t-PA/R275E,H417E	0.002	8.5	2.4×10^2

10

Molecular details of the stimulation of t-PA by fibrin, a complex process that almost certainly involves multiple points of contact between the two proteins, remain unclear. While fibrin stimulation of two-chain t-PA may occur through a single mechanism; stimulation of single chain t-PA by fibrin co-factors, however, appears to utilize at least two distinct mechanisms. First, fibrin apparently stimulates both single- and two-chain t-PA through a templating mechanism resulting in formation of a ternary complex which greatly augments the local concentration of enzyme and substrate. Second, because single- and two-chain t-PA have equivalent activity in the presence but not the absence of fibrin, it seems likely that binding to fibrin induces a conformational change in the activation domain of single chain t-PA. Similar activation of plasminogen upon binding to streptokinase as well as activation of prothrombin

20

by binding to staphylocoagulase have been described previously. Although the mechanism of this nonclassical, nonproteolytic activation of serine protease zymogens remains completely unclear, the behavior of single chain t-PA/R275E,H417D and t-PA/R275E,H417E indicates that His 417 does not play an essential role in this process. In addition, the properties of two-chain t-PA/H417D and t-PA/H417E indicate that His 417 does not play an essential role during zymogen activation of t-PA through the classical, proteolytic mechanism.

The primary effect of the H417D and H417E mutations was a selective reduction of the activity of single chain t-PA in the absence of fibrin and, consequently, an increase in the zymogenicity of the enzyme. At the molecular level this effect could be mediated either by stabilizing a less active, new conformation of single chain t-PA or by shifting the equilibrium between one or more existing conformations, with distinct activities, towards the less active conformation. Without being held to a single hypothesis, based on structural studies of trypsinogen, trypsin, chymotrypsinogen, and chymotrypsin, that the existence of an equilibrium among multiple conformations of the activation domain is likely to be a general feature of chymotrypsinogen family zymogens.

It is believed that the effect produced by converting His 417 to an acidic residue is mediated by disrupting the important salt bridge between Asp 477 and Lys 429 by providing an alternative, electrostatic interaction for Lys 429. The observation of an electrostatic interaction between K429 and E417 in the recently reported structure of the protease domain of two-chain u-PA, although the distance and geometry of this interaction vary somewhat in the two members of the unit cell in this study, lends credence to this hypothesis. Moreover, as observed in this study, formation of a new salt bridge between Lys 429 and Asp/Glu 417 would be expected to selectively suppress the activity of single chain t-PA because Lys 429 does not interact with Asp 477 in the two-chain enzyme. Instead, in two-chain t-PA, as in other mature chymotrypsin like enzymes, the mature amino terminus inserts into the activation pocket and plays this role. Consequently, as observed, two-chain t-PA/H417D and t-PA/H417E are expected to maintain high catalytic activity. Variants of t-PA containing an acidic residue at position 417, therefore, exhibit significantly enhanced zymogenicity.

Table IV

Stimulatory effect of fibrin on the catalytic efficiencies for variants of t-PA

Enzyme	Fold stimulation of k_{cat}/K_m
Two-Chain form	
t-PA	460
t-PA/H417D	290
t-PA/H417E	410
Single-chain form	
t-PA/R275E	6300
t-PA/R275E,H417D	48,200
t-PA/R275E,H417E	25,400

The extent of fibrin stimulation displayed by the single chain form of the mutated
 5 enzymes examined in this study is significantly greater than that displayed by wild type t-PA.
 Wild type, two-chain t-PA possesses a fibrin stimulation factor, defined as the ratio of the
 catalytic efficiencies in the presence and absence of fibrin, of approximately 460 (Table IV
 above). The two-chain variants display similar stimulation factors of 290 (t-PA/H417D) and
 410 (t-PA/H417E). Single chain wild type t-PA, with a fibrin stimulation factor of 6300, is
 10 stimulated to a substantially greater degree than the two-chain enzymes, presumable reflecting
 the ability of fibrin to stimulate the single chain enzymes not only through a templating
 mechanism but also by inducing nonproteolytic zymogen activation. Stimulation of single
 chain t-PA is further enhanced by the H417D or H417E mutations. The fibrin stimulation
 factors for single chain t-PA/R275E,H417D and t-PA/H417E are 48,200 and 25,400,
 15 respectively (Table IV above). Enhanced fibrin stimulation of the variants did not result from
 increased activity in the presence of fibrin but rather from decreased activity in the absence of
 a stimulator, an observation consistent with the belief that the effects of these mutations are
 mediated by disruption of a salt bridge between Lys 429 and Asp 477 in single chain t-PA.

The single chain form of a zymogen-like variant of t-PA is expected to exhibit reduced
 20 activity not only towards substrates (Tables I and III, above) but also towards specific
 inhibitors. To demonstrate this, we measured the second order rate constant for inhibition of

single chain t-PA/R275E, t-PA/R275E,H417D, and t-PA/R275E,H417E by the serpin plasminogen activator inhibitor, type 1 (PAI-1) (Table V below). As expected, both variants containing mutations at position 417 exhibited resistance to inhibition by PAI-1. The second order rate constant for inhibition by PAI-1 of t-PA/R275E,H417D or t-PA/R275E,H417E was reduced by factors of approximately 12 or 9, respectively, compared with t-PA/R275E.

Table V
Inhibition of wild type and variants of t-PA by PAI-1

Enzyme	Second Order Rate Constant ($M^{-1}s^{-1}$)
t-PA/R275E	1.8×10^6
t-PA/R275E,H417D	1.5×10^5
t-PA/R275E,H417E	2.1×10^5

t-PA exhibits unusually high catalytic activity as a single chain enzyme and consequently very low zymogenicity. By contrast, a closely related enzyme urokinase (u-PA) exhibits much lower catalytic activity as a single chain enzyme and substantially higher zymogenicity. An important finding of this study is that the presence or absence of a favorable electrostatic interaction between residues at positions 417 and 429 appears to be the major determinant of this key functional distinction between the two human plasminogen activators. The zymogenicity of wild type t-PA, u-PA, and t-PA containing an aspartate at position 417 are approximately 9, 250, and 150, respectively.

These studies demonstrated structure/function relationships within the activation domain of t-PA, and elucidated the molecular basis of important functional distinctions between t-PA and u-PA. These results can also aid the design of improved thrombolytic agents. For example t-PA/R275E,H417D, exhibits substantially enhanced fibrin stimulation, resistance to inhibition by PAI-1, and significantly increased zymogenicity, a useful combination of properties that enhances the therapeutic utility of the enzyme.

Example 2**Site Directed Mutagenesis And Construction Of
Expression Vectors Encoding Variants Of T-PA.**

5 Oligonucleotide directed site specific mutagenesis was performed as described in Example 1. The K429Y mutation was introduced into the 290 bp *SacI* – *SmaI* fragment of cDNA encoding t-PA that had been previously subcloned into bacteriophage M13mp18. The mutagenic primer had the following nucleotide sequence:

5' – CGGAGCGGCTGTATGAGGCTCATGT – 3' (SEQ ID NO: 10).

10 Following mutagenesis, ssDNA corresponding to the entire 290 bp *SacI* – *SmaI* fragment was fully sequenced to assure the presence of the desired mutation and the absence of any additional mutations. The sequence corresponding to the 290 bp *SacI* – *SmaI* fragment of the K429Y mutation is shown in SEQ ID NO: 7. Replicative form (RF) DNA was prepared for appropriate phage, and the mutated 290 bp *SacI* – *SmaI* fragment was recovered
15 after digestion of RF DNA with *SacI* and *SmaI* and electrophoresis of the digestion products on an agarose gel. The isolated, mutated *SacI* – *SmaI* fragment was used to replace the corresponding fragment in full length cDNAs encoding wild type t-PA or t-PA/R275E to yield new, full length cDNAs encoding t-PA/K429Y and t-PA/R275E,K429Y.

20 **Expression of enzymes by transient transfection of COS cells.**

cDNAs encoding t-PA, t-PA/R275E, t-PA/K429Y, and t-PA/R275E,K429Y were ligated into the transient expression vector pSVT7 and then introduced into COS cells by electroporation using a Bio Rad Gene pulser as described in Example 1. Following electroporation, cells were incubated overnight at 37 degrees Celsius in DMEM containing
25 10% fetal calf serum and 5mM sodium butyrate. Cells were then washed with serum free medium and incubated in DMEM for 48 hours at 37 degrees Celsius. After the incubation with serum free media, conditioned media were collected and enzyme concentrations were determined by ELISA.

30 **Purification of wild type and mutated variants of t-PA.**

Wild type and mutated variants of t-PA were purified using an FPLC system and a 1 ml HiTrap chelating column (Pharmacia Biotech). The column was charged with 0.1 M

CuSO₄ solution, washed with 5 – 10 ml distilled water, and equilibrated with start buffer (0.02 M NaHPO₄, pH 7.2, 1 M NaCl and 1 mM Imidazole). Conditioned medium containing wild type or variants of t-PA was adjusted to 1 M NaCl and injected into the column with a 50 ml superloop (Pharmacia Biotech). The column was then washed with 10 column volumes of start buffer and eluted using a 0 – 0.32 M linear gradient of imidazole in the same buffer. Peak fractions were collected and pooled. Purified t-PA samples were concentrated, and buffer was exchanged to 25 mM Tris (pH = 7.5), 50 mM NaCl, 1 mM EDTA, using a Centriplus 30 concentrator (Amicon).

10 **Kinetic analysis of t-PA activity using a small, synthetic substrate.**

The direct chromogenic assay utilized the substrate methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroaniline (Spectrozyme t-PA, American Diagnostica) and was performed as described in Example 1.

15 **Kinetic analysis of plasminogen activation using indirect chromogenic assays.**

Indirect chromogenic assays of t-PA utilized the substrates lys-plasminogen (American Diagnostica) and Spectrozyme PL (American Diagnostica) and were performed as previously described in Example 1. Assays were performed both in the presence and absence of the co-factor DESAFIB (American Diagnostica).

20

Indirect Chromogenic Assays in the presence of Various Fibrin Co-factors.

Standard indirect chromogenic assays were performed. Briefly, 0.25 – 1 ng of enzyme, 0.2 µM lys-plasminogen and 0.62 mM Spectrozyme PL were present in a total volume of 100 µl. Assays were performed either in the presence of buffer, 25 µg/ml DESAFIB, 100 µg/ml fibrinogen, 100 µg/ml cyanogen bromide fragments of fibrinogen (American Diagnostica), or 100 µg/ml of the stimulatory, thirteen amino acid peptide P368. P368 was kindly provided by Marshall Runge (University of Texas Medical Center, Galveston, TX.). Assays were performed in microtiter plates, and the optical density at 405 nm was measured every 30 seconds for one hour in a Molecular Devices Thermomax. Reactions were performed at 37 degrees Celsius.

25

30

Measurement of second order rate constants for inhibition by PAI-1.

Second order rate constants for the inhibition of wild type and mutated t-PA were measured under pseudo-first order conditions as described in Example 1.

5 Oligonucleotide directed site specific mutagenesis was used to produce a mutation of Lys 429 of t-PA that selectively suppressed the catalytic activity of single chain t-PA. Lysine 429 was replaced by a tyrosine residue to yield t-PA/K429Y. In addition, to permit accurate measurement of the enzymatic activity toward plasminogen of the single chain form of this variant, a noncleavable form of the mutated enzyme was constructed by introducing the
10 additional mutation R275E into the existing mutant to yield the R275E,K429Y variant.

Wild type t-PA, t-PA/R275E, t-PA/K429Y, and t-PA/R275E,K429Y were expressed by transient expression in COS 1 cells as described in Example 1. Since this procedure yielded predominantly single chain enzymes, two-chain t-PAs were generated by treating the enzyme preparations with plasmin-Sepharose. Quantitative conversion of the enzymes into
15 their mature, two-chain form was confirmed by SDS-PAGE. As previously demonstrated, variants containing the mutation R275E were synthesized and secreted exclusively as single chain enzymes and were not cleaved by plasmin-Sepharose.

Table VI

*Kinetic constants for cleavage of the chromogenic substrate
Spectrozyme t-PA by single- and two-chain t-PA variants*

Enzyme	$K_{cat}(s^{-1})$	$K_m(mM)$	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	40	0.5	8.0×10^4
t-PA/K429Y	35	0.5	7.0×10^4
Single-chain form			
t-PA/R275E	24	0.7	3.4×10^4
t-PA/R275E,K429Y	0.3	0.5	6.0×10^2

20 The enzymatic activity of the single and two-chain forms of wild type and t-PAs toward a small synthetic substrate is listed in Table VI above. Mutation of lysine 429 had little effect on the activity of two-chain t-PA. Two-chain t-PA/K429Y displayed approximately

90% of the activity of the two-chain, wild type enzyme in this assay. By contrast, the K429Y mutation had a very substantial effect on the activity of single chain t-PA. Single chain t-PA/R275E,K429Y exhibited approximately 2% of the activity of single chain t-PA/R275E. In this assay, the zymogenicity, defined as the ratio of the activities of the two-chain to that of the single chain form of a particular enzyme, was approximately 2.5 for wild type t-PA. By contrast, for variants containing the K429Y mutation, this ratio increased to approximately 117 (Table VI).

In the absence of a co-factor, the K429Y mutation had little effect on the activity of two-chain t-PA toward plasminogen; however, this mutation significantly reduced the catalytic efficiency of single chain t-PA (Table VII below). Compared with that of single chain t-PA/R275E, the activity of single chain t-PA/R275E,K429Y was reduced by a factor of 17. By contrast, the activities of two-chain t-PA and t-PA/K429Y differed by a factor of only 1.2.

Table VII

Kinetic constants for activation of plasminogen by single- and two-chain variants of t-PA in the absence of a cofactor

Enzyme	$K_{cat}(s^{-1})$	$K_m(\mu M)$	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	0.16	10	1.6×10^4
t-PA/K429Y	0.18	14	1.3×10^4
Single-chain form			
t-PA/R275E	[0.038]	[30]	1.3×10^3
t-PA/R275E,K429Y	0.00046	5.9	7.8×10^1

15

All of the variants analyzed in this study maintained reasonably high enzymatic activity towards the natural substrate plasminogen in the presence of the co-factor fibrin (Table VIII below). The single chain form of variants containing the K429Y mutation were, however, affected to a slightly greater extent than the corresponding mature, two-chain enzymes. Two-chain t-PA/K429Y possessed approximately 75% of the activity of two-chain t-PA while single chain t-PA/R275E,K429Y exhibited approximately 40% of the activity of single chain t-PA/R275E.

20

Table VIII
*Kinetic constants for activation of plasminogen by single- and
 two-chain t-PA variants in the presence of fibrin*

Enzyme	$K_{cat}(s^{-1})$	$K_m(\mu M)$	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	0.08	0.02	4.0×10^6
t-PA/K429Y	0.08	0.03	3.0×10^6
Single-chain form			
t-PA/R275E	0.10	0.02	5.0×10^6
t-PA/R275E,K429Y	0.10	0.07	2.0×10^6

The extent of fibrin stimulation displayed by the single chain form of t-PA/R275E,K429Y is significantly greater than that displayed by wild type t-PA. Wild type, two-chain t-PA possesses a fibrin stimulation factor, defined as the ratio of the catalytic efficiencies in the presence and absence of fibrin, of approximately 250 (Table IX below). The two-chain t-PA/K429Y variant displays a similar stimulation factor of 230. Single chain wild type t-PA, with a fibrin stimulation factor of 3800, is stimulated to a substantially greater degree than the two-chain enzymes, presumable reflecting the ability of fibrin to stimulate the single chain enzymes not only through a templating mechanism but also by inducing nonproteolytic zymogen activation. Stimulation of single chain t-Pa is further enhanced by the K429Y mutation. The fibrin stimulation factor for single chain t-PA/R275E,K429Y is approximately 26,000. Enhanced fibrin stimulation of the variant did not result from increased activity in the presence of fibrin but rather from decreased activity in the absence of a stimulator, an observation consistent with our proposal that the effects of these mutations are mediated by disruption of a salt bridge between Lys 429 and Asp 477 in single chain t-PA.

Table IX

Stimulatory effect of fibrin on the catalytic efficiencies for variants of t-PA

Enzyme	Fold stimulation of k_{cat}/K_m
Two-chain form	
t-PA	250
t-PA/K429Y	230
Single-chain form	
t-PA/R275E	3800
t-PA/R275E,K429Y	26,000

The mutated enzyme t-PA/R275E,K429Y is not only stimulated to a significantly greater extent by soluble fibrin than t-PA (Table IX above), but it is also substantially more discriminating among fibrin co-factors than the wild type enzyme (Fig. 2). The two-chain form of both wild type t-PA and t-PA/K429Y are strongly stimulated by soluble fibrin monomers (DESAFIB), fibrinogen, CNBr fragments of fibrinogen, and a 13 amino acid peptide (P368). Single chain t-PA/R275E, on the other hand, is stimulated strongly by soluble fibrin and fibrinogen and moderately by the CNBr fragments and peptide P368. In striking contrast to these enzymes, single chain t-PA/R275E,K429Y, although dramatically stimulated by fibrin monomers, is virtually nonresponsive to fibrinogen, CNBr fragments of fibrinogen, peptide P368.

The ratio of the specific activity of a plasminogen activator in the presence of fibrin to that in the presence of fibrinogen, or "fibrin selectivity factor", is one indication of the "clot selectivity" an enzyme will demonstrate in vivo. An enzyme with enhanced fibrin selectivity can accomplish efficient thrombolysis while displaying decreased systemic activity. Under the conditions of the assays reported here, the fibrin selectivity is 1.5 for two-chain t-PA, 1.5 for two-chain t-PA/K429Y, and 1.0 for single chain t-PA/R275E. The fibrin selectivity factor for single chain t-PA/R275E,K429Y, however, is 146. This double mutant, therefore, is approximately two orders of magnitude more discriminating between fibrin and fibrinogen than either single or two-chain wild type t-PA.

The single chain form of a zymogen-like variant of t-PA is expected to exhibit reduced activity not only towards substrates (Tables VI and VIII above) but also towards specific

inhibitors. The second order rate constant for inhibition of the single chain form of both t-PA/R275E and t-PA/R275E,K429Y by the serpin plasminogen activator inhibitor, type 1 (PAI-1), the primary physiological inhibitor of t-PA is shown in Table X below. As expected, t-PA/R275E,K429Y exhibited resistance to inhibition by PAI-1. The second order compared
5 with t-PA/R275E.

Table X
Inhibition of wild type and variants of t-PA by PAI-1

Enzyme	Second order rate constant ($M^{-1}s^{-1}$)
t-PA/R275E	1.8×10^6
t-PA/R275E,K429Y	7.7×10^3

An important finding of this study is that conversion of lysine 429 to tyrosine residue selectively suppresses the activity of single chain t-PA and thereby substantially enhances the zymogenicity of the enzyme. We have demonstrated, in addition, that single chain t-PA/R275E,K429Y is significantly more fibrin stimulated and substantially more fibrin selective than either single or two-chain, wild type t-PA. Single chain t-PA/R275E,K429Y also exhibits marked resistance to inhibition by PAI-1. It is believed that the effects of this mutation are mediated by disruption of a critical salt bridge formed by Lys 429 and Asp 477 that has been predicted to be present in single- but not two-chain t-PA. The primary role of this putative salt bridge is believed to be stabilization of the active conformation of single chain t-PA. Two-chain t-PA/K429Y, therefor, as demonstrated in this study, is expected to maintain high enzymatic activity.
10
15

These results aid in the design of improved thrombolytic agents. For Example t-PA/R275E,K429Y, exhibits significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.
20

The foregoing is intended to be illustrative of the present invention, but not limiting. Numerous variations and modifications of the present invention may be effected without departing from the true spirit and scope of the invention.
25

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- 5 (i) APPLICANT: Madison, Edwin L
- (ii) TITLE OF INVENTION: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA)
VARIANTS HAVING ZYMOGEN CHARACTERISTICS: COMPOSITIONS AND
10 METHODS OF USE
- (iii) NUMBER OF SEQUENCES: 1
- (iv) CORRESPONDENCE ADDRESS:
- 15 (A) ADDRESSEE: McDonnell Boehnen Hulbert & Berghoff
(B) STREET: 300 South Wacker Drive, 32nd Floor
(C) CITY: Chicago
(D) STATE: IL
(E) COUNTRY: USA
20 (F) ZIP: 60606
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
25 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
30 (B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Zimmerman, Roger P
35 (B) REGISTRATION NUMBER: 38,670
(C) REFERENCE/DOCKET NUMBER: 97,707
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: 312-913-0001
40 (B) TELEFAX: 312-913-0002
- (2) INFORMATION FOR SEQ ID NO:1:
- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 527 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant
50
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- 55 (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5	Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln	1 5 10 15
10	Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu	20 25 30
15	Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val	35 40 45
20	Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln	50 55 60
25	Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala	65 70 75 80
30	Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln	85 90 95
35	Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser Gly Ala Glu	100 105 110
40	Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly	115 120 125
45	Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys	130 135 140
50	Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala	145 150 155 160
55	Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly	165 170 175
60	Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His	180 185 190
65	Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile	195 200 205
70	Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu	210 215 220
75	Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys	225 230 235 240
80	Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys	245 250 255
85	Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro	260 265 270
90	Gln Phe Glu Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro	275 280 285
95	Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg	

- 30 -

	290	295	300
	Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala		
	305	310	315 320
5	Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile		
		325 330	335
10	Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe		
		340 345	350
	Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr		
		355 360	365
15	Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys		
		370 375	380
	Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp		
		385 390	395 400
20	Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys		
		405 410	415
	Asp Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His		
		420 425	430
25	Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn		
		435 440	445
30	Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly		
		450 455	460
	Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly		
		465 470	475 480
35	Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile		
		485 490	495
	Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr		
		500 505	510
40	Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro		
		515 520	525

45 2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 527 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

	Ser	Tyr	Gln	Val	Ile	Cys	Arg	Asp	Glu	Lys	Thr	Gln	Met	Ile	Tyr	Gln	1	5	10	15
10	Gln	His	Gln	Ser	Trp	Leu	Arg	Pro	Val	Leu	Arg	Ser	Asn	Arg	Val	Glu	20	25	30	
	Tyr	Cys	Trp	Cys	Asn	Ser	Gly	Arg	Ala	Gln	Cys	His	Ser	Val	Pro	Val	35	40	45	
15	Lys	Ser	Cys	Ser	Glu	Pro	Arg	Cys	Phe	Asn	Gly	Gly	Thr	Cys	Gln	Gln	50	55	60	
20	Ala	Leu	Tyr	Phe	Ser	Asp	Phe	Val	Cys	Gln	Cys	Pro	Glu	Gly	Phe	Ala	65	70	75	80
	Gly	Lys	Cys	Cys	Glu	Ile	Asp	Thr	Arg	Ala	Thr	Cys	Tyr	Glu	Asp	Gln	85	90	95	
25	Gly	Ile	Ser	Tyr	Arg	Gly	Thr	Trp	Ser	Thr	Ala	Glu	Ser	Gly	Ala	Glu	100	105	110	
	Cys	Thr	Asn	Trp	Asn	Ser	Ser	Ala	Leu	Ala	Gln	Lys	Pro	Tyr	Ser	Gly	115	120	125	
30	Arg	Arg	Pro	Asp	Ala	Ile	Arg	Leu	Gly	Leu	Gly	Asn	His	Asn	Tyr	Cys	130	135	140	
35	Arg	Asn	Pro	Asp	Arg	Asp	Ser	Lys	Pro	Trp	Cys	Tyr	Val	Phe	Lys	Ala	145	150	155	160
	Gly	Lys	Tyr	Ser	Ser	Glu	Phe	Cys	Ser	Thr	Pro	Ala	Cys	Ser	Glu	Gly	165	170	175	
40	Asn	Ser	Asp	Cys	Tyr	Phe	Gly	Asn	Gly	Ser	Ala	Tyr	Arg	Gly	Thr	His	180	185	190	
	Ser	Leu	Thr	Glu	Ser	Gly	Ala	Ser	Cys	Leu	Pro	Trp	Asn	Ser	Met	Ile	195	200	205	
45	Leu	Ile	Gly	Lys	Val	Tyr	Thr	Ala	Gln	Asn	Pro	Ser	Ala	Gln	Ala	Leu	210	215	220	
50	Gly	Leu	Gly	Lys	His	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Asp	Ala	Lys	225	230	235	240
	Pro	Trp	Cys	His	Val	Leu	Lys	Asn	Arg	Arg	Leu	Thr	Trp	Glu	Tyr	Cys	245	250	255	
55	Asp	Val	Pro	Ser	Cys	Ser	Thr	Cys	Gly	Leu	Arg	Gln	Tyr	Ser	Gln	Pro	260	265	270	
	Gln	Phe	Glu	Ile	Lys	Gly	Gly	Leu	Phe	Ala	Asp	Ile	Ala	Ser	His	Pro	275	280	285	

- 32 -

	Trp	Gln	Ala	Ala	Ile	Phe	Ala	Lys	His	Arg	Arg	Ser	Pro	Gly	Glu	Arg	
	290						295					300					
5	Phe	Leu	Cys	Gly	Gly	Ile	Leu	Ile	Ser	Ser	Cys	Trp	Ile	Leu	Ser	Ala	
	305					310					315					320	
	Ala	His	Cys	Phe	Gln	Glu	Arg	Phe	Pro	Pro	His	His	Leu	Thr	Val	Ile	
					325					330					335		
10	Leu	Gly	Arg	Thr	Tyr	Arg	Val	Val	Pro	Gly	Glu	Glu	Glu	Gln	Lys	Phe	
				340					345					350			
	Glu	Val	Glu	Lys	Tyr	Ile	Val	His	Lys	Glu	Phe	Asp	Asp	Asp	Thr	Tyr	
15			355					360					365				
	Asp	Asn	Asp	Ile	Ala	Leu	Leu	Gln	Leu	Lys	Ser	Asp	Ser	Ser	Arg	Cys	
	370						375					380					
20	Ala	Gln	Glu	Ser	Ser	Val	Val	Arg	Thr	Val	Cys	Leu	Pro	Pro	Ala	Asp	
	385					390					395					400	
	Leu	Gln	Leu	Pro	Asp	Trp	Thr	Glu	Cys	Glu	Leu	Ser	Gly	Tyr	Gly	Lys	
					405					410					415		
25	Glu	Glu	Ala	Leu	Ser	Pro	Phe	Tyr	Ser	Glu	Arg	Leu	Lys	Glu	Ala	His	
				420						425				430			
	Val	Arg	Leu	Tyr	Pro	Ser	Ser	Arg	Cys	Thr	Ser	Gln	His	Leu	Leu	Asn	
30			435					440					445				
	Arg	Thr	Val	Thr	Asp	Asn	Met	Leu	Cys	Ala	Gly	Asp	Thr	Arg	Ser	Gly	
		450				455						460					
35	Gly	Pro	Gln	Ala	Asn	Leu	His	Asp	Ala	Cys	Gln	Gly	Asp	Ser	Gly	Gly	
	465					470					475					480	
	Pro	Leu	Val	Cys	Leu	Asn	Asp	Gly	Arg	Met	Thr	Leu	Val	Gly	Ile	Ile	
					485					490					495		
40	Ser	Trp	Gly	Leu	Gly	Cys	Gly	Gln	Lys	Asp	Val	Pro	Gly	Val	Tyr	Thr	
				500					505					510			
	Lys	Val	Thr	Asn	Tyr	Leu	Asp	Trp	Ile	Arg	Asp	Asn	Met	Arg	Pro		
45				515				520					525				

2) INFORMATION FOR SEQ ID NO:3:

- 50 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 527 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: not relevant
- 55 (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

- 33 -

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

10 Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln
 1 5 10 15
 Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu
 20 25 30
 15 Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val
 35 40 45
 20 Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln
 50 55 60
 Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala
 65 70 75 80
 25 Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln
 85 90 95
 Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser Gly Ala Glu
 100 105 110
 30 Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly
 115 120 125
 Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys
 130 135 140
 Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala
 145 150 155 160
 40 Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly
 165 170 175
 Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His
 180 185 190
 45 Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile
 195 200 205
 Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu
 210 215 220
 Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys
 225 230 235 240
 55 Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys
 245 250 255
 Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro
 260 265 270

- 34 -

Gln Phe Glu Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro
 275 280 285
 5 Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg
 290 295 300
 Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala
 305 310 315 320
 10 Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile
 325 330 335
 Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe
 340 345 350
 15 Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr
 355 360 365
 20 Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys
 370 375 380
 Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp
 385 390 395 400
 25 Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys
 405 410 415
 His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Tyr Glu Ala His
 420 425 430
 30 Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn
 435 440 445
 35 Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly
 450 455 460
 Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly
 465 470 475 480
 40 Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile
 485 490 495
 Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr
 500 505 510
 45 Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro
 515 520 525

50

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 290 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: not relevant
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CTACGGCAAG	CATGAGGCCT	TGTCTCCTTT	CTATTCGGAG	CGGCTGAAGG	AGGCTCATGT	60
CAGACTGTAC	CCATCCAGCC	GCTGCACATC	ACAACATTTA	CTTAACAGAA	CAGTCACCGA	120
CAACATGCTG	TGTGCTGGAG	ACACTCGGAG	CGGCGGGCCC	CAGGCAAAC	TGCACGACGC	180
CTGCCAGGGC	GATTCGGGAG	GCCCCCTGGT	GTGTCTGAAC	GATGGCCGCA	TGACTTTGGT	240
GGGCATCATC	AGCTGGGGCC	TGGGCTGTGG	ACAGAAGGAT	GTCCCGGGTG		290

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 290 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTACGGCAAG	GACGAGGCCT	TGTCTCCTTT	CTATTCGGAG	CGGCTGAAGG	AGGCTCATGT	60
CAGACTGTAC	CCATCCAGCC	GCTGCACATC	ACAACATTTA	CTTAACAGAA	CAGTCACCGA	120
CAACATGCTG	TGTGCTGGAG	ACACTCGGAG	CGGCGGGCCC	CAGGCAAAC	TGCACGACGC	180
CTGCCAGGGC	GATTCGGGAG	GCCCCCTGGT	GTGTCTGAAC	GATGGCCGCA	TGACTTTGGT	240
GGGCATCATC	AGCTGGGGCC	TGGGCTGTGG	ACAGAAGGAT	GTCCCGGGTG		290

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 290 base pairs

- 36 -

(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

5 (ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTACGGCAAG GAGGAGGCCT TGTCTCCTTT CTATTCGGAG CGGCTGAAGG AGGCTCATGT	60
20 CAGACTGTAC CCATCCAGCC GCTGCACATC ACAACATTTA CTTAACAGAA CAGTCACCGA	120
CAACATGCTG TGTGCTGGAG ACACTCGGAG CGGCGGGCCC CAGGCAAAC TGCACGACGC	180
CTGCCAGGGC GATTCGGGAG GCCCCCTGGT GTGTCTGAAC GATGGCCGCA TGACTTTGGT	240
25 GGGCATCATC AGCTGGGGCC TGGGCTGTGG ACAGAAGGAT GTCCCGGGTG	290

30

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 290 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: not relevant

35

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

40

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

50 CTACGGCAAG CATGAGGCCT TGTCTCCTTT CTATTCGGAG CGGCTGTATG AGGCTCATGT	60
CAGACTGTAC CCATCCAGCC GCTGCACATC ACAACATTTA CTTAACAGAA CAGTCACCGA	120
CAACATGCTG TGTGCTGGAG ACACTCGGAG CGGCGGGCCC CAGGCAAAC TGCACGACGC	180
55 CTGCCAGGGC GATTCGGGAG GCCCCCTGGT GTGTCTGAAC GATGGCCGCA TGACTTTGGT	240
GGGCATCATC AGCTGGGGCC TGGGCTGTGG ACAGAAGGAT GTCCCGGGTG	290

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTACGGCAAG GACGAGGCCT TGT

23

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTACGGCAAG GAGGAGGCCT TGT

23

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

5 (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGAGCGGCT GTATGAGGCT MCATGT

25

I claim:

1. A variant single chain human tissue-type plasminogen activator protein having R275
5 and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue thereby disrupting the salt bridge interaction between aspartate 477 and lysine 429.
2. The protein of claim 1 wherein the non-basic amino acid residue is chosen from the
10 group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid and having a zymogenicity of at least 10.
3. The protein of claim 1 having a zymogenicity of at least 50.
4. The protein of claim 1 having a zymogenicity of at least 100.
5. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.
6. The protein of claim 1 having a fibrin stimulation factor of at least 20,000.
- 15 7. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.
8. The protein of claim 2 having a fibrin stimulation factor of at least 20,000.
9. The protein of claim 3 having a fibrin stimulation factor of at least 20,000.
10. The protein of claim 1 wherein the protein is at least a factor of 5 less inhibited by
20 PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.
11. The protein of claim 1 wherein the protein is at least a factor of 9 less inhibited by
PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
12. The protein of claim 1 wherein the protein is at least a factor of 200 less inhibited by
25 PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
13. The protein of claim 8 wherein the protein is at least a factor of 9 less inhibited by
PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
- 30 14. The protein of claim 8 wherein the protein is at least a factor of 200 less inhibited by
PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
15. The protein of claim 1 wherein the protein has a fibrin selectivity factor of at least 100.
16. The protein of claim 8 wherein the protein has a fibrin selectivity factor of at least 100.

17. The protein of claim 14 wherein the protein has a fibrin selectivity factor of at least 100.
- 5 18. A polynucleotide encoding the protein of claim 1.
19. An expression vector comprising the polynucleotide of claim 18.
20. A cell comprising the expression vector of claim 19.
21. A variant single chain human tissue-type plasminogen activator protein selected from the group consisting of R275E,H417D, R275E,H417E and R275E,K429Y.
- 10 22. A polynucleotide encoding the protein of claim 21.
23. An expression vector comprising the polynucleotide of claim 22.
24. A cell comprising the expression vector of claim 23.
25. A composition for the treatment of an thrombotic condition comprising a physiologically effective amount of the protein of claim 1 in a pharmaceutically
15 suitable excipient.
26. The composition of claim 25 wherein the dose of the protein is from about 0.05 milligram per kilogram body weight to about 0.2 milligrams per kilogram body weight.
27. A diagnostic kit comprising antibodies to the protein of claim 1.
- 20 28. A diagnostic kit comprising the protein of claim 1.
29. A diagnostic kit comprising polynucleotides capable of hybridizing to the polynucleotide of claim 18.
30. A method of making a variant single chain human tissue-type plasminogen activator protein comprising the steps of culturing the cell of claim 24.
- 25 31. The method of claim 30 further comprising the additional step of purifying the protein.

1/5

GTTCTGAGCACAGGGCTGGAGAGAAAACCTCTGCGAGGAAAGGGAAGGAGCAAGCCGTGA

										-35											-30
										met	asp	ala	met	lys	arg	gly	leu				
										ATG	GAT	GCA	ATG	AAG	AGA	GGG	CTC				
																	-20				
cys	cys	val	leu	leu	leu	cys	gly	ala	val	phe	val	ser	pro	ser							
TGC	TGT	GTG	CTG	CTG	CTG	TGT	GGA	GCA	GTC	TTC	GTT	TCG	CCC	AGC							
														-10			1				
gln	glu	ile	his	ala	arg	phe	arg	arg	gly	ala	arg	SER	TYR	GLN							
CAG	GAA	ATC	CAT	GCC	CGA	TTC	AGA	AGA	GGA	GCC	AGA	TCT	TAC	CAA							
														10							
VAL	ILE	CYS	ARG	ASP	GLU	LYS	THR	GLN	MET	ILE	TYR	GLN	GLN	HIS							
GTG	ATC	TGC	AGA	GAT	GAA	AAA	ACG	CAG	ATG	ATA	TAC	CAG	CAA	CAT							
														20			30				
GLN	SER	TRP	LEU	ARG	PRO	VAL	LEU	ARG	SER	ASN	ARG	VAL	GLU	TYR							
CAG	TCA	TGG	CTG	CGC	CCT	GTG	CTC	AGA	AGC	AAC	CGG	GTG	GAA	TAT							
														40							
CYS	TRP	CYS	ASN	SER	GLY	ARG	ALA	GLN	CYS	HIS	SER	VAL	PRO	VAL							
TGC	TGG	TGC	AAC	AGT	GGC	AGG	GCA	CAG	TGC	CAC	TCA	GTG	CCT	GTC							
														50			60				
LYS	SER	CYS	SER	GLU	PRO	ARG	CYS	PHE	ASN	GLY	GLY	THR	CYS	GLN							
AAA	AGT	TGC	AGC	GAG	CCA	AGG	TGT	TTC	AAC	GGG	GGC	ACC	TGC	CAG							
														70							
GLN	ALA	LEU	TYR	PHE	SER	ASP	PHE	VAL	CYS	GLN	CYS	PRO	GLU	GLY							
CAG	GCC	CTG	TAC	TTC	TCA	GAT	TTC	GTG	TGC	CAG	TGC	CCC	GAA	GGA							
														80			90				
PHE	ALA	GLY	LYS	CYS	CYS	GLU	ILE	ASP	THR	ARG	ALA	THR	CYS	TYR							
TTT	GCT	GGG	AAG	TGC	TGT	GAA	ATA	GAT	ACC	AGG	GCC	ACG	TGC	TAC							
														100							
GLU	ASP	GLN	GLY	ILE	SER	TYR	ARG	GLY	THR	TRP	SER	THR	ALA	GLU							
GAG	GAC	CAG	GGC	ATC	AGC	TAC	AGG	GGC	ACG	TGG	AGC	ACA	GCG	GAG							
														110			120				
SER	GLY	ALA	GLU	CYS	THR	ASN	TRP	ASN	SER	SER	ALA	LEU	ALA	GLN							
AGT	GGC	GCC	GAG	TGC	ACC	AAC	TGG	AAC	AGC	AGC	GCG	TTG	GCC	CAG							
														130							
LYS	PRO	TYR	SER	GLY	ARG	ARG	PRO	ASP	ALA	ILE	ARG	LEU	GLY	LEU							
AAG	CCC	TAC	AGC	GGG	CGG	AGG	CCA	GAC	GCC	ATC	AGG	CTG	GGC	CTG							
														140			150				
GLY	ASN	HIS	ASN	TYR	CYS	ARG	ASN	PRO	ASP	ARG	ASP	SER	LYS	PRO							
GGG	AAC	CAC	AAC	TAC	TGC	AGA	AAC	CCA	GAT	CGA	GAC	TCA	AAG	CCC							

FIG. 1A

2 / 5

```

160
TRP CYS TYR VAL PHE LYS ALA GLY LYS TYR SER SER GLU PHE CYS
TGG TGC TAC GTC TTT AAG GCG GGG AAG TAC AGC TCA GAG TTC TGC

170
SER THR PRO ALA CYS SER GLU GLY ASN SER ASP CYS TYR PHE GLY
AGC ACC CCT GCC TGC TCT GAG GGA AAC AGT GAC TGC TAC TTT GGG

180
ASN GLY SER ALA TYR ARG GLY THR HIS SER LEU THR GLU SER GLY
AAT GGG TCA GCC TAC CGT GGC ACG CAC AGC CTC ACC GAG TCG GGT

190
ALA SER CYS LEU PRO TRP ASN SER MET ILE LEU ILE GLY LYS VAL
GCC TCC TGC CTC CCG TGG AAT TCC ATG ATC CTG ATA GGC AAG GTT

200
TYR THR ALA GLN ASN PRO SER ALA GLN ALA LEU GLY LEU GLY LYS
TAC ACA GCA CAG AAC CCC AGT GCC CAG GCA CTG GGC CTG GGC AAA

210
HIS ASN TYR CYS ARG ASN PRO ASP GLY ASP ALA LYS PRO TRP CYS
CAT AAT TAC TGC CGG AAT CCT GAT GGG GAT GCC AAG CCC TGG TGC

220
HIS VAL LEU LYS ASN ARG ARG LEU THR TRP GLU TYR CYS ASP VAL
CAC GTG CTG AAG AAC CGC AGG CTG ACG TGG GAG TAC TGT GAT GTG

230
PRO SER CYS SER THR CYS GLY LEU ARG GLN TYR SER GLN PRO GLN
CCC TCC TGC TCC ACC TGC GGC CTG AGA CAG TAC AGC CAG CCT CAG

240
PHE ARG ILE LYS GLY GLY LEU PHE ALA ASP ILE ALA SER HIS PRO
TTT CGC ATC AAA GGA GGG CTC TTC GCC GAC ATC GCC TCC CAC CCC

250
TRP GLN ALA ALA ILE PHE ALA LYS HIS ARG ARG SER PRO GLY GLU
TGG CAG GCT GCC ATC TTT GCC AAG CAC AGG AGG TCG CCC GGA GAG

260
ARG PHE LEU CYS GLY GLY ILE LEU ILE SER SER CYS TRP ILE LEU
CGG TTC CTG TGC GGG GGC ATA CTC ATC AGC TCC TGC TGG ATT CTC

270
SER ALA ALA HIS CYS PHE GLN GLU ARG PHE PRO PRO HIS HIS LEU
TCT GCC GCC CAC TGC TTC CAG GAG AGG TTT CCG CCC CAC CAC CTG

280
THR VAL ILE LEU GLY ARG THR TYR ARG VAL VAL PRO GLY GLU GLU
ACG GTG ATC TTG GGC AGA ACA TAC CGG GTG GTC CCT GGC GAG GAG

```

FIG. 1B

3/5

GLU	GLN	LYS	PHE	GLU	VAL	GLU	LYS	TYR	ILE	VAL	HIS	LYS	GLU	PHE
GAG	CAG	AAA	TTT	GAA	GTC	GAA	AAA	TAC	ATT	GTC	CAT	AAG	GAA	TTC
ASP	ASP	ASP	THR	TYR	ASP	ASN	ASP	ILE	ALA	LEU	LEU	GLN	LEU	LYS
GAT	GAT	GAC	ACT	TAC	GAC	AAT	GAC	ATT	GCG	CTG	CTG	CAG	CTG	AAA
SER	ASP	SER	SER	ARG	CYS	ALA	GLN	GLU	SER	SER	VAL	VAL	ARG	THR
TCG	GAT	TCG	TCC	CGC	TGT	GCC	CAG	GAG	AGC	AGC	GTG	GTC	CGC	ACT
VAL	CYS	LEU	PRO	PRO	ALA	ASP	LEU	GLN	LEU	PRO	ASP	TRP	THR	GLU
GTG	TGC	CTT	CCC	CCG	GCG	GAC	CTG	CAG	CTG	CCG	GAC	TGG	ACG	GAG
CYS	GLU	LEU	SER	GLY	TYR	GLY	LYS	HIS	GLU	ALA	LEU	SER	PRO	PHE
TGT	GAG	CTC	TCC	GGC	TAC	GGC	AAG	CAT	GAG	GCC	TTG	TCT	CCT	TTC
TYR	SER	GLU	ARG	LEU	LYS	GLU	ALA	HIS	VAL	ARG	LEU	TYR	PRO	SER
TAT	TCG	GAG	CGG	CTG	AAG	GAG	GCT	CAT	GTC	AGA	CTG	TAC	CCA	TCC
SER	ARG	CYS	THR	SER	GLN	HIS	LEU	LEU	ASN	ARG	THR	VAL	THR	ASP
AGC	CGC	TGC	ACA	TCA	CAA	CAT	TTA	CTT	AAC	AGA	ACA	GTC	ACC	GAC
ASN	MET	LEU	CYS	ALA	GLY	ASP	THR	ARG	SER	GLY	GLY	PRO	GLN	ALA
AAC	ATG	CTG	TGT	GCT	GGA	GAC	ACT	CGG	AGC	GGC	GGG	CCC	CAG	GCA
ASN	LEU	HIS	ASP	ALA	CYS	GLN	GLY	ASP	SER	GLY	GLY	PRO	LEU	VAL
AAC	TTG	CAC	GAC	GCC	TGC	CAG	GGC	GAT	TCG	GGA	GGC	CCC	CTG	GTG
CYS	LEU	ASN	ASP	GLY	ARG	MET	THR	LEU	VAL	GLY	ILE	ILE	SER	TRP
TGT	CTG	AAC	GAT	GGC	CGC	ATG	ACT	TTG	GTG	GGC	ATC	ATC	AGC	TGG
GLY	LEU	GLY	CYS	GLY	GLN	LYS	ASP	VAL	PRO	GLY	VAL	TYR	THR	LYS
GGC	CTG	GGC	TGT	GGA	CAG	AAG	GAT	GTC	CCG	GGT	GTG	TAC	ACC	AAG
VAL	THR	ASN	TYR	LEU	ASP	TRP	ILE	ARG	ASP	ASN	MET	ARG	PRO	OP
GTT	ACC	AAC	TAC	CTA	GAC	TGG	ATT	CGT	GAC	AAC	ATG	CGA	CCG	TGA

FIG. 1C

4/5

CCAGGAACACCCGACTCCTCAAAAGCAAATGAGATCCCGCCTCTTCTTCTTCAGAAGACA
CTGCAAAGGCGCAGTGCTTCTCTACAGACTTCTCCAGACCCACCACACCGCAGAAGCGGG
ACGAGACCCTACAGGAGAGGGAAGAGTGCATTTTCCAGATACTTCCCATTTTGGAAGT
TTTCAGGACTTGGTCTGATTTTCAGGATACTCTGTCAGATGGGAAGACATGAATGCACACT
AGCCTCTCCAGGAATGCCTCCTCCCTGGGCAGAAAGTGGCCATGCCACCCTGTTTTCAGCTA
AAGCCCAACCTCCTGACCTGTCACCGTGAGCAGCTTTGGAAACAGGACCACAAAAATGAA
AGCATGTCTCAATAGTAAAAGATAACAAGATCTTTCAGGAAAGACGGATTGCATTAGAA
ATAGACAGTATATTTATAGTCACAAGAGCCAGCAGGGCCTCAAAGTTGGGGCAGGCTGGC
TGGCCCGTCATGTTCTCCTCAAAAGCACCTTGACGTCAAGTCTCCTTCCCCTTTCCCCACT
CCCTGGCTCTCAGAAGGTATTCCTTTTGTGTACAGTGTGTAAAGTGTAATCCTTTTTCT
TTATAAACTTTAGAGTAGCATGAGAGAATTGTATCATTTGAACAAGTAGGCTTCAGCATA
TTTATAGCAATCCATGTTAGTTTTTACTTTCTGTTGCCACAACCCTGTTTTATACTGTA
CTTAATAAATTCAGATATATTTTTTCACAGTTTTTCCAAAAAAAAAAAAA

FIG. 1D

5/5

FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/20226

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N9/72 //C12N15/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PETERSEN L C ET AL: "QUENCHING OF THE AMIDOLYTIC ACTIVITY OF ONE-CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR BY MUTATION OF LYSINE-416" BIOCHEMISTRY, vol. 29, no. 14, 1990, WASHINGTON US, pages 3451-3457, XP002053064	1-4, 18-20, 25, 26, 29
Y	see the whole document, especially page 3452, column 2, last paragraph - page 3453, column 3, first paragraph and page 3456, column 1, last paragraph --- -/--	21-24



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

8 May 1998

Date of mailing of the international search report

22/05/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/US 97/20226

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TACHIAS K ET AL: "Variants of tissue-type plasminogen activator which display substantially enhanced stimulation by fibrin" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 31, 4 August 1995, BALTIMORE US, pages 18319-18322, XP002063362 see the whole document ---	1,2,5-9, 15-17
Y	WO 90 02798 A (GENENTECH INC) 22 March 1990 cited in the application see page 2, line 28 - page 5, line 38 see page 10, line 19 - line 40 see page 11, line 31 - line 35 see page 19, line 22 - page 20, line 25 see page 31, line 11 - page 32, line 13 see page 33, line 14 - line 35	21-24
A	---	1-9, 15-20, 25,26, 30,31
A	EP 0 199 574 A (GENENTECH INC) 29 October 1986 cited in the application see page 3, line 4 - page 8, line 8 see page 10, line 4 - line 26 see page 24, line 25 - page 30, line 4 -----	1-4, 18-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/20226

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9002798 A	22-03-90	US 5108901 A	28-04-92
		AT 124452 T	15-07-95
		AU 626323 B	30-07-92
		AU 4194689 A	02-04-90
		DE 68923298 D	03-08-95
		DK 36991 A	02-05-91
		EP 0457758 A	27-11-91
		HU 213922 B	28-11-97
		IE 67508 B	03-04-96
		IL 91306 A	14-08-97
		IL 109735 A	20-11-97
		IL 111767 A	15-04-97
		JP 4500157 T	16-01-92
		US 5520913 A	28-05-96
		US 5405771 A	11-04-95
		US 5411871 A	02-05-95
		US 5616486 A	01-04-97
		US 5614190 A	25-03-97
		US 5156969 A	20-10-92
		US 5728567 A	17-03-98
		US 5714145 A	03-02-98
		US 5258180 A	02-11-93
		US 5262170 A	16-11-93
EP 0199574 A	29-10-86	AU 596356 B	03-05-90
		AU 5641686 A	30-10-86
		DE 3613390 A	30-10-86
		DE 3682104 A	28-11-91
		DE 3689386 D	27-01-94
		DE 3689386 T	19-05-94
		DK 181286 A	23-10-86
		DK 181386 A	23-10-86
		EP 0200451 A	05-11-86
		FI 861673 A,B,	23-10-86
		FR 2581652 A	14-11-86
		GB 2173804 A,B	22-10-86
		IE 62206 B	28-12-94
		IE 58574 B	06-10-93
		JP 2529816 B	04-09-96
		JP 6277071 A	04-10-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Appl. No.

PCT/US 97/20226

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0199574 A		JP 7040940 B	10-05-95
		JP 62000024 A	06-01-87
		NO 175216 B	06-06-94
		PT 82429 B	03-03-88
		US 5736134 A	07-04-98
		US 5714372 A	03-02-98
		US 5073494 A	17-12-91
		US 5147643 A	15-09-92
		US 5219569 A	15-06-93
<hr/>			

PATENT COOPERATION TREATY



PCT

REC'D 04 MAR 1999

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 97,707		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US97/20226	International filing date (day/month/year) 12/11/1997	Priority date (day/month/year) 12/11/1996	
International Patent Classification (IPC) or national classification and IPC C12N9/72			
Applicant THE SCRIPPS RESEARCH INSTITUTE et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 9 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 4 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none">I <input checked="" type="checkbox"/> Basis of the reportII <input checked="" type="checkbox"/> PriorityIII <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicabilityIV <input type="checkbox"/> Lack of unity of inventionV <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statementVI <input type="checkbox"/> Certain documents citedVII <input type="checkbox"/> Certain defects in the international applicationVIII <input type="checkbox"/> Certain observations on the international application			
Date of submission of the demand 10/06/1998		Date of completion of this report	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0 Tx: 523656 epmu d Fax: (+49-89) 2399-4465		Authorized officer van Heusden, M Telephone No. (+49-89) 2399 8145 	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US97/20226

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-4,6-11,13-27	as originally filed	
5,12	with telefax of	14/01/1999

Claims, No.:

1-16	with telefax of	14/01/1999
17-32	with telefax of	28/01/1999

Drawings, sheets:

1/5-5/5	as originally filed
---------	---------------------

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

see separate sheet

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US97/20226

☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 27, 29.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 27, 29 are so unclear that no meaningful opinion could be formed (*specify*):

see separate sheet

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US97/20226

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement.

1. Statement

Novelty (N)	Yes:	Claims	2-17, 21-26, 28, 30-32
	No:	Claims	1, 18-20
Inventive step (IS)	Yes:	Claims	3-17, 32
	No:	Claims	1-2, 18-26, 28, 30-31
Industrial applicability (IA)	Yes:	Claims	1-26, 28, 30-32
	No:	Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US97/20226

Additional remarks to section I:

The amendment to claim 3 (replacement of 'zymogenicity of at least **50**' for 'at least **75**') does not have a basis in the application as originally filed. Although the applicant indicates p. 7, line 2 as the basis for the amendment, this passage discloses a zymogenicity of at least 10, preferably of a range of about 50 to about 200. Therefore the specific value of **75** is not disclosed and the amendment introduces a random selection of the range as originally disclosed. The amendment fulfills the requirements of Article 19(2) and Rule 70.2(c) only if the applicant can show a basis for the specific value of **75** in the application as originally filed.

Additional remarks to section II:

The priority document pertaining to the present application was not available at the time of establishing this IPER. Hence, the current assessment is based on the assumption that all claims enjoy priority rights from the filing date of the priority document.

Additional remarks to section III:

Claims 27 and 29 cannot be examined because of lack of clarity. Claim 27 refers to a diagnostic kit comprising antibodies to the t-PA variant of the present invention, and lacks clarity in that it does not provide any technical specification of said antibodies. Therefore it is impossible to compare the subject matter of this claim with the prior art. Moreover, antibodies against the t-PA variant of the present invention could be reactive against any part of the protein, including any epitope outside the region of the substituted amino acids. Therefore the antibodies could react with wild-type t-PA, which could result in a lack of novelty.

Similarly, claim 29 refers to polynucleotides capable of hybridizing to the polynucleotide encoding the t-PA variant of the present invention. This claim also lacks clarity in that it does not provide any technical specification of said

polynucleotides. Therefore, also for this claim it is impossible to compare the subject matter to the prior art. In addition, a polynucleotide as defined in claim 29 could hybridize with any part of the t-PA variant polynucleotide, also outside the region of the substituted amino acids, and thus also with wild-type tPA polynucleotides, which could result in an objection for lack of novelty. Even if the polynucleotides would be complementary to the region containing the substituted amino acids, depending on the length of the polynucleotides and the hybridization conditions, said polynucleotides could still be hybridizing to wild-type t-PA.

Additional remarks to section V:

1. Citations

The documents mentioned in this IPER are numbered as in the International Search Report (ISR), i.e. D1 corresponds to the first document of the ISR etc.

The following document is cited from examiner's own knowledge:

D5: EP-A-0351246

A copy of this document is annexed to the communication.

2. Novelty (Article 33(2) PCT)

- 2.1 The present application discloses a variant single chain human tissue-type plasminogen activator (t-PA) protein having R275 and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue. It further discloses a polynucleotide encoding said t-PA, an expression vector comprising said polynucleotide and a cell comprising said vector. It further relates to a composition comprising said t-PA variant for treatment of a thrombotic condition, as well as diagnostic kits.
- 2.2 The present application does not satisfy the criterion set forth in Article 33(2) PCT because the subject matter of claims 1 and 18-20 is not novel in respect of

document D1.

- 2.3 Document D1 discloses a t-PA variant having a R275L substitution and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue (K277L, see abstract). The subject matter of claim 1 includes the additional functional feature 'thereby disrupting the salt bridge interaction between aspartate 477 and lysine 429'. This feature is not a measurable parameter and is therefore meaningless for the definition of the scope of the claim. Indeed, the specification does not report any test that could be used to assess this functional feature. In addition, this feature is entirely hypothetical as indicated by the applicant himself (p. 18, l. 16; p. 19, l. 17; p. 25, l. 15 and p. 27 l. 13 and 16). Therefore this feature has not been taken into account when assessing novelty of claim 1.

D1 also describes the DNA encoding the variant, an expression vector containing said DNA and a cell comprising said expression vector (p. 3452, left column, l. 7-right column, l. 6). Therefore D1 anticipates the subject matter of claims 1 and 18-20.

3. Inventive step (Article 33(3) PCT)

- 3.1 The present application does not satisfy the criterion set forth in Article 33(3) PCT because the subject matter of claims 2, 21-26, 28 and 30-31 does not involve an inventive step.
- 3.2 The closest prior art to assess the inventiveness of the subject matter of claim 2 is document D1, which discloses a t-PA variant in which R275 is substituted for glycine and a second t-PA variant in which one other basic amino acid residue in the serine protease region (K416) is substituted for serine (see abstract). This second K416S-t-PA variant has a zymogenicity of 57 (p. 3454, Table II). The subject matter of claim 2 differs from the teachings in D1 only in that the two substitutions are combined in one t-PA variant. Document D2 teaches the combination of a substitution at the proteolytic cleavage site (the R275E substitution) with an additional substitution in the serine protease region of t-PA that decreases proteolytic activity of the single chain zymogen and thus increases

zymogenicity. It would be obvious for the skilled person to combine the teachings of these two documents, to arrive at the t-PA variant as defined in claim 2.

- 3.3 The closest prior art to evaluate the inventiveness of the subject matter of claim 21 is document D2. D2 discloses a t-PA variant comprising the R275E substitution in combination with a second substitution F305H that increases zymogenicity (see abstract and Figure 1). The subject matter of claim 21 differs from the teachings in D2 only in that the R275E substitution is combined with a different second substitution. Therefore the problem to be solved by the present invention may be regarded as finding a further second substitution that increases zymogenicity. D1 indicates that H417 may be involved in the putative salt-bridge interaction that is responsible for the enzyme activity of the zymogen (p. 3453, left column, l. 21-24). Both D1 (Fig. 2 and Table II) and D5 (Fig. 6A) show that a combination substitution of K416S,H417T results in decreased proteolytic activity of the single chain zymogen and thus in increased zymogenicity. No inventive skill is required to choose the H417 amino acid from these two substitutions, and to substitute it with further non-basic amino acids, to arrive at the R275E,H417D or the R275E,H417E t-PA variant of the present invention.

Moreover, no surprising effect is obtained with the R275E,H417(D/E) t-PA variants since their zymogenicity (17 and 13, respectively, p. 16, Table 1) is much lower than that of the K416S t-PA variant of D1 (57, p. 3454, Table II).

D5 further discloses a DNA encoding the variant (claims 15-18), in an expression vector (claim 19), in a host cell (claim 20), and a composition for treatment of a thrombotic condition, comprising the t-PA variant (p. 5, l. 59 - p. 6, l. 2). It also discloses a method for making the t-PA variant recombinantly (claims 24 and 25). Therefore also claims 22-26, 28 and 30-31 are objected to for lack of inventive step.

- 3.4 The applicant is already informed that, in the case that the above objection to claim 21 for lack of inventive step can be overcome, an objection for lack of unity will be raised. The general concept linking together the three embodiments of claim 21 appears to be either claim 1, which is not novel as argued above under 2.3, or claim 2, which is not inventive as argued above under 3.2.

3.5 The third embodiment of the present application is the R275E,K429Y t-PA variant. Document D3 discloses a combination substitution of E426,R427,K429,E430 which results in decreased proteolytic activity of the single chain zymogen and thus in increased zymogenicity (Tables I and II). However, D3 does not indicate which of these four substitutions is responsible for the observed changes in enzyme activity. In addition, D1 indicates that K429 is not likely to be involved in the putative salt-bridge formation. Therefore it would not be obvious for the skilled person to test the K429Y substitution. Thus an inventive step can be recognized for the R275E,K429Y t-PA variant as claimed in claim 32. Claims 22-26, 28 and 30-31 would fulfill the requirements of inventive step only in so far as they refer to said inventive t-PA variant.

4. Industrial applicability (Article 33(4) PCT)

Claims 1-26, 28 and 30-32 are considered to have industrial applicability.

I claim:

1. A variant single chain human tissue-type plasminogen activator protein having R275
5 and at least one other basic amino acid residue in the serine protease region substituted
by a non-basic amino acid residue thereby disrupting the salt bridge interaction
between aspartate 477 and lysine 429.
2. The protein of claim 1 wherein the non-basic amino acid residue is chosen from the
10 group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic
acid, and glutamic acid and having a zymogenicity of at least 10.
3. The protein of claim 1 having a zymogenicity of at least 50.
4. The protein of claim 1 having a zymogenicity of at least 100.
5. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.
6. The protein of claim 1 having a fibrin stimulation factor of at least 20,000.
- 15 7. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.
8. The protein of claim 2 having a fibrin stimulation factor of at least 20,000.
9. The protein of claim 3 having a fibrin stimulation factor of at least 20,000.
10. The protein of claim 1 wherein the protein is at least a factor of 5 less inhibited by
PAI-1 compared to wild type single chain human tissue-type plasminogen activator
20 protein.
11. The protein of claim 1 wherein the protein is at least a factor of 9 less inhibited by
PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
12. The protein of claim 1 wherein the protein is at least a factor of 200 less inhibited by
25 PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
13. The protein of claim 8 wherein the protein is at least a factor of 9 less inhibited by
PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
- 30 14. The protein of claim 8 wherein the protein is at least a factor of 200 less inhibited by
PAI-1 compared to wild type single chain human tissue-type plasminogen activator
protein.
15. The protein of claim 1 wherein the protein has a fibrin selectivity factor of at least 100.
16. The protein of claim 8 wherein the protein has a fibrin selectivity factor of at least 100.

REPLACED BY
ART 34 AMDT

17. The protein of claim 14 wherein the protein has a fibrin selectivity factor of at least 100.
- 5 18. A polynucleotide encoding the protein of claim 1.
19. An expression vector comprising the polynucleotide of claim 18.
20. A cell comprising the expression vector of claim 19.
21. A variant single chain human tissue-type plasminogen activator protein selected from the group consisting of R275E,H417D, R275E,H417E and R275E,K429Y.
- 10 22. A polynucleotide encoding the protein of claim 21.
23. An expression vector comprising the polynucleotide of claim 22.
24. A cell comprising the expression vector of claim 23.
25. A composition for the treatment of an thrombotic condition comprising a physiologically effective amount of the protein of claim 1 in a pharmaceutically suitable excipient.
- 15 26. The composition of claim 25 wherein the dose of the protein is from about 0.05 milligram per kilogram body weight to about 0.2 milligrams per kilogram body weight.
27. A diagnostic kit comprising antibodies to the protein of claim 1.
- 20 28. A diagnostic kit comprising the protein of claim 1.
29. A diagnostic kit comprising polynucleotides capable of hybridizing to the polynucleotide of claim 18.
30. A method of making a variant single chain human tissue-type plasminogen activator protein comprising the steps of culturing the cell of claim 24.
- 25 31. The method of claim 30 further comprising the additional step of purifying the protein.

REPLACED BY
ART 34 AMDT

therapeutic compositions thus include the cDNA compounds themselves as naked DNA, presented as part of a viral vector delivery system or other vector-based gene expression delivery system, presented in a liposome delivery system and the like.

The recombinant expressed t-PA variant proteins of the present invention are contemplated as thrombolytic therapeutic agents for ameliorating the same conditions outlined above. Based on the individual structural and functional properties of various t-PA variant proteins described above, the selection of the particular t-PA variant is determined by the desired therapeutic outcome. For example, the fibrinogen-mediated activation of endogenous human t-PA is activated by bleeding which then results in a widespread undesired systemic response. Thus, to mediate fibrinolytic processes locally in either an acute or chronic thrombotic condition while simultaneously preventing proteolytic activation systemically, one would therefore use the t-PA variant, namely R275E,K429Y, that is primarily activated by fibrin and not fibrinogen. A composition for use as thrombolytic therapeutic agents generally a physiologically effective amount of the t-PA variant protein in a pharmaceutically suitable excipient. Depending on the mode of administration and the condition to be treated, the thrombolytic therapeutic agents are administered in single or multiple doses. If "bolus" doses are administered, doses of about 0.01 to about 0.6 mg/kg will typically be administered, preferably doses of about 0.05 to about 0.2 mg/kg, with subsequent administrations of about 0.1 to about 0.2 mg/kg to maintain a t-PA blood level of about 3 microgram/ml. One skilled in the art will appreciate that variations in dosage depend on the condition to be treated. In other applications, a composition of variant t-PA in a gel composition is useful in preventing the formation of adhesions.

Other variations and uses of the present invention will be apparent to one skilled in the art.

Example 1

Site Directed Mutagenesis And Construction Of Expression Vectors Encoding Variants Of T-PA

Oligonucleotide directed site specific mutagenesis was performed by the method of Zoller and Smith (Zoller, M. I., and Smith, M. (1984) DNA 3, 479-488) as modified by Kunkel (Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 488-492). Mutations were introduced into the 290 bp *SacI* - *SmaI* fragment of cDNA encoding t-PA that had been

REPLACED BY
ART 34 AMDT

del-51-173), PCT 87/04722 (deletion of all or part of the N-terminal 1 - 91), EPO Publ. No. 231,624 (all of growth factor domain deleted), and EPO Publ. No. 242,836 and Jap. Pat. Appl. Kokai No. 62 - 269688 (some or all of the growth factor domain deleted).

It has further been shown that t-PA can be modified both in the region of the first
5 kringle domain and in the growth factor domain, resulting in increased circulatory half-life. See EPO Pat. Publ. No. 241,208 published Oct. 14, 1987. The region between amino acids 51 and 87, inclusive, can be deleted from t-PA to result in a variant having slower clearance from plasma. Browne et al., *J. Biol. Chem.*, 263: 1599-1602 (1988). Also, t-PA can be
10 modified, without adverse biological effects, in the region of amino acids 67 to 69 of the mature, native t-PA, by deletion of certain amino acid residues or replacement of one or more amino acids with different amino acids. See EPO Pat. Publ. No. 240,334 published Oct. 7, 1987.

A hybrid of t-PA/urokinase using the region of t-PA encompassing amino acids 273 -
15 527 is also disclosed. See EPO 290,118 published Nov. 9, 1988. Serpin-resistant mutants of human t-PA with alterations in the protease domain, including del296-302 t-PA, R304S t-PA, and R304E t-PA, are disclosed in Madison et al., *Nature*, 339: 721-724 (1989). The above list is not an exhaustive review of the numerous variants of t-PA that have described.

As a result of the catalytic activity of precursor t-PA, despite effective clot lysis at
20 targeted sites, undesirable proteolysis occurs systemically resulting in the deleterious depletion of circulating fibrinogen, α_2 -anti-plasmin and plasminogen. What is needed are more zymogenic t-PA variant proteins that provide effective local clot lysis is achieved with diminished systemic proteolytic effects.

Summary of the Invention

25 The present invention provides single chain variant t-PA proteins having at least two substitutions of basic amino acid residues by neutral or acidic amino acid residues, compared to the wild-type human t-PA, as well as polynucleotides encoding such single chain variant t-PA proteins. The single chain variant t-PA proteins of the present invention have the R275
30 amino acid residue substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. Preferably the single chain variant t-PA proteins of the present invention have the R275 amino

REPLACED BY
ART 34 AMDT